Acasti’s CaPre Flunks Phase III Triglyceride TrialAmerican Heart Association, Clinical Data, Clinical Trials, Placebo, Primary Endpoints, R&D, Stocks, TriglyceridesAcasti Pharma announced topline data from the company’s Phase III TRILOGY 2 trial of CaPre (omega-3 phospholipid) to reduce severe triglyceride levels. Read more September 1, 2020/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/09/Acastis-CaPre-Flunks-Phase-III-Triglyceride-Trial-BioSpace-9-1-20.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-09-01 11:51:482020-09-01 21:33:02Acasti’s CaPre Flunks Phase III Triglyceride Trial